



Whereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-325200US
Client Ref. No.: E-157-1997/0-US-08
Customer No.: 20350

Mail Stop Sequence

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

On

11 Dec. 2003

TOWNSEND and TOWNSEND and CREW LLP

By:

Malinda Adajit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RYBACK *et al.*

Application No.: 09/918,887

Filed: July 30, 2001

For: IMMUNOTOXINS DIRECTED
AGAINST MALIGNANT CELLS

Customer No.: 20350

Confirmation No. 54276

Examiner: Schwadron, Ronald B.

Technology Center/Art Unit: 1644

COMMUNICATION UNDER 37 C.F.R. §§
1.821-1.825 AND AMENDMENT

Mail Stop Sequence

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed December 4, 2003, Applicants submit herewith the required corrected paper copy of the Substitute Sequence Listing, along with a copy of the computer readable form.

The **Amendments to the Specification** begin on page 2 of this paper.

Remarks begin on page 3 of this paper.